Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system
ObjectiveBortezomib, carfilzomib and ixazomib are the proteasome inhibitors (PIs) used to treat multiple myeloma (MM). We conducted a comprehensive pharmacovigilance analysis of their neurotoxicity using the Food and Drug Administration Adverse Event Reporting System (FAERS), including not only peri...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Frontiers Media S.A.
2026-01-01
|
| 叢編: | Frontiers in Pharmacology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1712361/full |
| 標簽: |
沒有標簽, 成為第一個標記此記錄!
|